Novartis Pharma Stein AG (full-cycle manufacturing)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Dosage form: tablets

ATC: L01EG02

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Dosage form: tablets

ATC: L01EG02

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Dosage form: tablets

ATC: L01EG02

The drug is used to treat chronic iron overload in patients with beta-thalassemia and other types of anemia requiring regular blood transfusions. It is also used in transfusion-independent thalassemia syndromes if the patient exhibits iron excess.

Dosage form: tablets, dispersible

ATC: V03AC03

The drug is used to treat chronic iron overload in patients with beta-thalassemia (aged 6 years and older) and other anemias requiring regular blood transfusions. It is also used for patients with non-transfusion-dependent thalassemia syndromes if iron overload is detected.

Dosage form: tablets, dispersible

ATC: V03AC03

The drug is prescribed for the treatment of chronic myeloid leukemia (CML) in adults and children, acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), and chronic eosinophilic leukemia (CEL). It is also used for the treatment of gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma protuberans (DFSP).

Dosage form: tablets, film-coated

ATC: L01EA01

The drug is prescribed for the treatment of chronic myeloid leukemia (CML) in adults and children, acute lymphoblastic leukemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), and chronic eosinophilic leukemia (CEL). It is also used for the treatment of gastrointestinal stromal tumors (GIST) and dermatofibrosarcoma protuberans (DFSP).

Dosage form: tablets, film-coated

ATC: L01EA01

The drug is intended for the maintenance therapy of adult patients with chronic obstructive pulmonary disease (COPD) to facilitate airway dilation.

Dosage form: capsules, hard

ATC: R03AC18

The drug is used for maintenance therapy in adults with chronic obstructive pulmonary disease (COPD) to dilate the airways.

Dosage form: capsules, hard

ATC: R03AC18

It is used to treat adults with chronic myeloid leukemia (CML) with the Philadelphia chromosome. The drug is prescribed for both newly diagnosed disease and in cases where previous therapy (e.g., imatinib) has been ineffective or is unsuitable for the patient.

Dosage form: capsules, hard

ATC: L01EA03

The drug is used for the treatment of adult patients with chronic myeloid leukemia (Ph+ CML). It is prescribed for both newly diagnosed chronic phase and for chronic or accelerated phase, if previous therapy (e.g., imatinib) has been ineffective or intolerable.

Dosage form: capsules, hard

ATC: L01EA03

The drug is used to prevent symptoms associated with bone damage (e.g., pathological fractures or spinal compression) in patients with advanced-stage malignant neoplasms. It is also prescribed for the treatment of tumor-induced hypercalcemia.

Dosage form: concentrate for infusion solution

ATC: M05BA08